Drug Watch

Data presented at ACNP meeting demonstrated safety, tolerability, and efficacy for SPN-820 for MDD.

Check out 2 new psychopharmacology innovations!

Intra-Cellular Therapies has submitted an sNDA for lumateperone for the treatment of major depressive disorder in adults as adjunctive therapy to antidepressants.

In the phase 3 ENCORE trial, AXS-12 reduced the frequency of cataplexy attacks as compared with placebo at week 3 of the double-blind period.

Calling it a barrier to care, FDA committees decide to end clozapine REMS.

How is the study of muscarinic receptors transforming schizophrenia treatment?

Check out new results of a pharmacokinetics study of AD04, an investigational therapeutic agent for the treatment of alcohol use disorder in patients with heavy drinking.

There is an accumulating body of evidence that metformin may have benefits in aging beyond its effect on glycemic control.

Emraclidine once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoints in the 2 phase 2 EMPOWER trials.

The medication treatment of schizophrenia has finally diversified to a novel neurotransmitter system: the muscarinic cholinergic system.

The authors of the Clinician's Corner column discuss the latest FDA-approved treatment for schizophrenia.

New positive results demonstrate the efficacy and safety of lumateperone (Caplyta) 42 mg for the prevention of relapse in adult patients with schizophrenia.

Posters from Psych Congress confirm the durability of long-term treatment with xanomeline/trospium (Cobenfy).

Although safety and tolerability was positive, ALTO-100 failed to reach primary endpoint in MDD study.

Here's what you need to know about the latest FDA-approved schizophrenia treatment.

Learn more about the new positive efficacy, safety, tolerability data from the phase 3 SOLARIS trial, which were presented at the 37th Annual European College of Neuropsychopharmacology Congress.

New data shared at ECNP Congress informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of Perseris to risperidone (Uzedy).

The FDA has granted Fast Track designation to liafensine for the treatment of patients with treatment-resistant depression.

Novel treatment for cocaine use disorder? Researchers performed a randomized, double-blind, placebo-controlled trial of lorcaserin.

The vice president of Clinical Development and Medical Affairs, Mental Health at Boehringer Ingelheim shares why it is such an unprecedented moment for schizophrenia research.

Cobenfy: Only the first in a new upcoming class of antipsychotics.

While there is still a lot to learn about Cobenfy, here's why it marks a historic moment in the treatment of schizophrenia.

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.

Check out new positive efficacy, safety, and tolerability results from the phase 3 SOLARIS trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.

A new analysis from a 3-year open-label extension study revealed that treatment with deutetrabenazine was associated with long term improvement of symptoms of tardive dyskinesia.

How comfortable do you feel in your knowledge of this type of treatment?

Later this month, the FDA will vote on KarXT, a novel muscarinic acetylcholine receptor agonist.

Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?